Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There has recently been increased occasions to treat patients complicated with psychiatric and nervous disorders, in accordance with the rise of interest in human right and the improved social acceptance of these diseases. In the past, most cases were reluctantly terminated because of the prejudice against diseases and anxiety about the teratogenicity of the drugs. In this paper, the management of pregnancy and delivery including neonatal period are discussed. 1) Epilepsy Epilepsy is one of the most common medical complications of pregnancy with about 0.5%. Pregnancy has no obvious effect on epilepsy. Although the teratogenicity of the antiepileptic drugs has been repeatedly reported, anticonvulsant therapy should be continued during pregnancy. Because the risk of the fetal brain damage from hypoxia under the epileptic convulsion of the untreated patients is higher than that of the teratogenicity of drugs. Phenobarbital or phenytoin are commonly used. Trimethadione which has been used for the petit mal epilepsy should not be used because of the high potent of teratogenicity. The serum concentrations of these drugs tend to decrease in the third trimester. Therefore the frequent monitoring of the serum drug concentration is very important. The monitoring of the blood clotting factors after delivery is also very important to avoid the neonatal vitamin K deficiency bleeding. Vitamin K is administered if required. Breast feeding is not contraindicated. Withdrawal syndrome in the neonatal state should not be overlooked. 2) Schizophrenia Pregnancy has no effect on schizophrenia. The teratogenicity of chlorpromazine or haloperidol in human pregnancy is thought to be negative. The function of the fetal central nervous system is suppressed with antipsychotic drugs.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Psychiatric and nervous disorders]. 197 12

Genome-wide association studies (GWAS) and proteomic studies have provided convincing evidence implicating alterations in immune/inflammatory processes in schizophrenia. However, despite the convergence of evidence, direct links between the genetic and proteomic findings are still lacking for schizophrenia. We investigated associations between single nucleotide polymorphisms (SNPs) from the custom-made PsychArray and the expression levels of 190 multiplex immunoassay profiled serum proteins in 149 schizophrenia patients and 198 matched controls. We identified associations between 81 SNPs and 29 proteins, primarily involved in immune/inflammation responses. Significant SNPxDiagnosis interactions were identified for eight serum proteins including Factor-VII[rs555212], Alpha-1-Antitrypsin[rs11846959], Interferon-Gamma Induced Protein 10[rs4256246] and von-Willebrand-Factor[rs12829220] in the control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vitamin K-Dependent Protein S[rs6123] in the schizophrenia group; Interleukin-6 receptor[rs7553796] in both the control and schizophrenia groups. These results suggested that the effect of these SNPs on expression of the respective proteins varies with diagnosis. The combination of patient-specific genetic information with blood biomarker data opens a novel approach to investigate disease mechanisms in schizophrenia and other psychiatric disorders. Our findings not only suggest that blood protein expression is influenced by polymorphisms in the corresponding gene, but also that the effect of certain SNPs on expression of proteins can vary with diagnosis.
 ...
PMID:Associations between SNPs and immune-related circulating proteins in schizophrenia. 2897 76